Although IGF-1 and IGBP-3 have been reported to be altered in previous studies performed in atherosclerosis and other cardiovascular diseases, we found no significant differences between the two peptides among patients with hepatitis, cirrhosis or pancreatitis [55–56]. This evidence concerns the gene IGF1 and hepatitis A virus infection.